Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2005

View Archived Issues

European orphan drug designation for NAFB-001

NVA-237 enters phase IIb trial for COPD

Cand5 begins phase II for wet AMD

Tysabri safety evaluation completed with no new cases of PML

Results for Neugene compounds in Ebola, Marburg, anthrax and ricin models

New pivotal study for ceftobiprole to broaden indication

Trigen completes financing in support of pipeline development

5-HT2A receptor antagonists from Sankyo prove to be beneficial for pancreatitis

SM-197378 reduces myocardial infarct size in vivo

Confirmation of SSR-149415's antidepressant potential

Artemisinin combination therapies for malaria

BioCryst files SPA for Fodosine trial in relapsed or refractory T-cell leukemia

MedImmune completes acquisition of Cellective Therapeutics

Agensys and Merck to codevelop and commercialize AGS-PSCA for cancer

MLN-518 begins phase I/II study with chemotherapy for AML

Nastech begins development of intranasal rapid-acting insulin

Kissei seeks Japanese approval for Glufast with alpha-glucosidase inhibitor

New title added to the Drug R&D Backgrounders topic list --Osteogenesis Imperfecta

Novel FXR agonists emerge from Intercept R&D

Recent patents describe novel antiinfective agents

Preliminary phase II data on the antitumor efficacy of AS-1404 in lung cancer announced

Phase III data on Polyphenon E in the treatment of external anogenital warts

M01ZH09 typhoid vaccine reported safe and immunogenic in human volunteers

Altana patents claim gastric acid antisecretory agents

Abatacept effective in refractory rheumatoid arthritis

PROVE IT-TIMI 22 studies detail benefits of statins in acute coronary syndromes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...